Product Development

Most cell and gene therapy products are regulated as medicinal products in the EU and the US; as such their development must result in data that confirm quality, safety and efficacy.  
 
One of the key objectives of
 Product development, aside from demonstration of clinical efficacy, is to fully understand the characteristics of the product and the process used to make it. Characterisation is central to product development, this figure provides an overview of the scope of characterisation activities and how they interrelate.

Effective development processes provide all the tools necessary to implement changes, and these tools are a result of thorough characterisation.  Implementation of changes to the manufacture of medicinal products requires that the product before and after the change is comparable.  Comparability is a central concept in the regulation of medicinal products; this tool provides an overview of the various parameters that might be required for a comparability exercise. 

 

Regulatory Tools (last update)

Product development (Jul-11)

Importance of Characterisation (Aug-08) 

Comparability  (Oct-11)

Regulatory Considerations for Technology Transfer  (Feb-12)

Use of reference materials  (Nov-11)

Agency Advice (EU/US) (Nov-11)

 

Regulatory Guidance (last update)

There remains a paucity of specific guidance on the development of ATMP’s, however much of the existing guidance is also indirectly relevant since it provides the principles. 

Existing ICH guidelines with applicability to cell-based medicinal products:

ICH guidelines (May-17)

EMA guidelines (Aug-17)

FDA guidelines (May-17)

Guidelines related to Reference Materials  (Mar-15)

Comparability guidelines  (Oct-11)

Pharmacopoeial chapters with relevance to cell-based medicinal products:

PhEur (Feb-15)

USP (Aug-11)

Note: These figures do not include hyperlinks since the content requires subscription.
 
Note: This is a work in progress and currently high-level, a number of sections are combined and soem are not discussed.  Only ICH-evel guidelines are identified so far.

Instructions: Many of these tools are interactive and can be expanded or collapsed by clicking on the (+).  Alternatively you can expand or collapse levels by right clicking on the diagram and selecting the required level.  

Links to external documents are included and indicated by the following symbol Simply click to open the document in a new tab.

Some tools contain notes, hover or click on note symbol   to see note.


Feedback

We value your feedback; should you have comments or suggestions for inclusions and amendments please let us know. Contact: info@advbiols.com

 

Acknowledgements

These tools were developed with the support of a grant from the Technology Strategy Board as part of the VALUE consortium (Regenerative Medicine Value Systems: Navigating the Uncertainties) lead by Biolatris Ltd (http://www.biolatris.com).